Stocks
Intra-Cellular Therapies Financial Statements (ITCI) |
||||||||||
| Intra-Cellular Therapiessmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 03.08.2023 | 02.11.2023 | 22.02.2024 | 07.05.2024 | 07.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 94.7 | 110.1 | 125.8 | 131.5 | 144.9 | 512.3 | |||
| Operating Income, bln rub | -48.4 | -47.2 | -29.7 | -34.1 | -21.0 | -131.9 | ||||
| EBITDA, bln rub | ? | -48.4 | -47.2 | -29.6 | -34.0 | -20.8 | -131.5 | |||
| Net profit, bln rub | ? | -44.1 | -42.8 | -24.3 | -28.6 | -15.2 | -110.9 | |||
| OCF, bln rub | ? | -60.1 | -36.8 | -25.3 | -2.06 | -34.1 | -98.2 | |||
| CAPEX, bln rub | ? | 0.000 | 0.000 | 0.268 | 0.001 | 0.000 | 0.269 | |||
| FCF, bln rub | ? | -60.1 | -36.8 | -25.5 | -2.06 | -34.1 | -98.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 136.4 | 150.1 | 146.4 | 154.9 | 155.9 | 607.4 | ||||
| Cost of production, bln rub | 6.75 | 7.16 | 9.13 | 10.7 | 9.90 | 36.9 | ||||
| R&D, bln rub | 38.0 | 49.8 | 41.6 | 50.8 | 42.8 | 185.0 | ||||
| Interest expenses, bln rub | 4.35 | 0.000 | 0.000 | 4.35 | 0.000 | 4.35 | ||||
| Assets, bln rub | 722.2 | 713.6 | 717.7 | 728.3 | 747.0 | 747.0 | ||||
| Net Assets, bln rub | ? | 627.6 | 607.1 | 600.7 | 591.4 | 599.5 | 599.5 | |||
| Debt, bln rub | 18.5 | 18.0 | 17.5 | 16.9 | 16.4 | 16.4 | ||||
| Cash, bln rub | 538.7 | 512.9 | 493.0 | 497.9 | 477.4 | 477.4 | ||||
| Net debt, bln rub | -520.2 | -494.9 | -475.5 | -481.0 | -461.0 | -461.0 | ||||
| Ordinary share price, rub | 54.2 | 63.3 | 52.1 | 71.6 | 69.2 | 52.3 | ||||
| Number of ordinary shares, mln | 95.1 | 95.9 | 96.1 | 96.3 | 96.9 | 96.9 | ||||
| Market cap, bln rub | 5 152 | 6 075 | 5 008 | 6 896 | 6 704 | 5 070 | ||||
| EV, bln rub | ? | 4 631 | 5 581 | 4 533 | 6 415 | 6 243 | 4 609 | |||
| Book value, bln rub | 628 | 607 | 601 | 591 | 599 | 599 | ||||
| EPS, rub | ? | -0.46 | -0.45 | -0.25 | -0.30 | -0.16 | -1.14 | |||
| FCF/share, rub | -0.63 | -0.38 | -0.27 | -0.02 | -0.35 | -1.02 | ||||
| BV/share, rub | 6.60 | 6.33 | 6.25 | 6.14 | 6.19 | 6.19 | ||||
| EBITDA margin, % | ? | -51.1% | -42.8% | -23.5% | -25.8% | -14.4% | -25.7% | |||
| Net margin, % | ? | -46.5% | -38.8% | -19.3% | -21.7% | -10.5% | -21.6% | |||
| FCF yield, % | ? | -4.81% | -3.12% | -3.23% | -1.80% | -1.47% | -1.94% | |||
| ROE, % | ? | -34.9% | -29.3% | -24.7% | -23.6% | -18.5% | -18.5% | |||
| ROA, % | ? | -30.3% | -24.9% | -20.7% | -19.2% | -14.8% | -14.8% | |||
| P/E | ? | -23.5 | -34.2 | -33.8 | -49.4 | -60.5 | -45.7 | |||
| P/FCF | -20.8 | -32.1 | -31.0 | -55.4 | -68.0 | -51.5 | ||||
| P/S | ? | 16.7 | 16.7 | 12.0 | 14.9 | 13.1 | 9.90 | |||
| P/BV | ? | 8.21 | 10.0 | 8.34 | 11.7 | 11.2 | 8.46 | |||
| EV/EBITDA | ? | -19.4 | -28.1 | -26.3 | -40.3 | -47.5 | -35.0 | |||
| Debt/EBITDA | 2.17 | 2.49 | 2.76 | 3.02 | 3.50 | 3.50 | ||||
| R&D/CAPEX, % | 15 504% | 5 077 400% | 68 755% | |||||||
| CAPEX/Revenue, % | 0.00% | 0.00% | 0.21% | 0.00% | 0.00% | 0.05% | ||||
| Intra-Cellular Therapies shareholders | ||||||||||
